Immunoglobulin and t cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1307-1313

  Logan, Aaron C ^a   Vashi, Nikita ^b   Faham, Malek ^c   Carlton, Victoria ^c   Kong, Katherine ^c   Buño, Ismael ^d   Zheng, Jianbiao ^c   Moorhead, Martin ^c   Klinger, Mark ^c   Zhang, Bing ^b   Waqar, Amna ^b   Zehnder, James L ^b   Miklos, David B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sequenta Inc   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic cell transplantation; High throughput sequencing; Minimal residual disease; Next generation sequencing

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; CLONAL VARIATION; FEMALE; GENE AMPLIFICATION; GENE LOCUS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; T LYMPHOCYTE RECEPTOR GENE; ALLOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; GENES, T-CELL RECEPTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84905579254     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.018     Document Type: Article

References (37)

1. Bruggemann M., Gokbuget N., Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012, 39:47-57.
2. Bunin N., Johnston D.A., Roberts W.M., et al. Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. Br J Haematol 2003, 120:711-715.
3. Conter V., Bartram C.R., Valsecchi M.G., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
4. Bader P., Hancock J., Kreyenberg H., et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002, 16:1668-1672.
5. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998, 92:4072-4079.
6. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998, 102:860-871.
7. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
8. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
9. Gokbuget N., Kneba M., Raff T., et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012, 120:1868-1876.
10. EuroMRD. EuroMRD: a division of European Scientific Foundation for Laboratory HematoOncology (ESHLO). Available at: Accessed November 13,2013. http://www.euromrd.org.
11. van Dongen J.J., Orfao A., EuroFlow C. EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia 2012, 26:1899-1907.
12. Bruggemann M., Raff T., Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL?. Blood 2012, 120:4470-4481.
13. Scrideli C.A., Queiroz R.G., Bernardes J.E., et al. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification. Med Pediatr Oncol 2003, 41:10-16.
14. Ryan J., Quinn F., Meunier A., et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol 2009, 144:107-115.
15. Malec M., van der Velden V.H., Bjorklund E., et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004, 18:1630-1636.
16. Neale G.A., Coustan-Smith E., Stow P., et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
17. van der Velden V.H., Jacobs D.C., Wijkhuijs A.J., et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002, 16:1432-1436.
18. Faham M., Zheng J., Moorhead M., et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012, 120:5173-5180.
19. Assumpcao J.G., Ganazza M.A., de Araujo M., et al. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy. Pediatr Blood Cancer 2010, 55:1278-1286.
20. Dawidowska M., Jolkowska J., Szczepanski T., et al. Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience. Arch Immunol Ther Exp (Warsz.) 2008, 56:409-418.
21. Toubai T., Tanaka J., Ota S., et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol 2005, 80:181-187.
22. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
23. Csinady E., van der Velden V.H., Joas R., et al. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis. Leukemia 2009, 23:870-876.
24. van der Velden V.H., Bruggemann M., Hoogeveen P.G., et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia 2004, 18:1971-1980.
25. Wu D., Sherwood A., Fromm J.R., et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012, 4:134ra63.
26. Logan A.C., Gao H., Wang C., et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 2011, 108:21194-21199.
27. Logan A.C., Zhang B., Narasimhan B., et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013, 27:1659-1665.
28. Boyd S.D., Marshall E.L., Merker J.D., et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009, 1:12ra23.
29. Armand P., Oki Y., Neuberg D.S., et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2013, 163:123-126.
30. Campbell P.J., Pleasance E.D., Stephens P.J., et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 2008, 105:13081-13086.
31. Imashuku S., Terui K., Matsuyama T., et al. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant 2003, 31:1127-1135.
32. Trageser D., Iacobucci I., Nahar R., et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. JExp Med 2009, 206:1739-1753.
33. Gawad C., Pepin F., Carlton V.E., et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 2012, 120:4407-4417.
34. Brisco M.J., Latham S., Sutton R., et al. Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. JMol Diagn 2009, 11:194-200.
35. Uzunel M., Jaksch M., Mattsson J., Ringden O. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 2003, 122:788-794.
36. Topp M.S., Gokbuget N., Zugmaier G., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012, 120:5185-5187.
37. Klinger M., Brandl C., Zugmaier G., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012, 119:6226-6233.